

Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers


SUPPLEMENTARY MATERIALS




Supplementary Figure 1: Size distribution analysis of microvesicles. The size and number of microvesicles isolated from ESFT cell lines as determined by NTA analysis.



Supplementary Figure 2: Pathway analysis of ESFT sEV core proteome. (A) FunRich analysis of common ESFT sEV proteins. (B–D) PANTHER (Protein Analysis Through Evolutionary Relationships) analysis results of molecular functions (B), biological functions (C), and protein classes of ESFT sEVs (D).



Supplementary Figure 3: IHC analysis of CD99 and HINT1 in ESFT tissue samples. (A–B) NGFR staining. (C–D) CD99 staining.



Supplementary Figure 4: Comparison of ESFT sEVs isolated through COMBO or CD9 immuno-isolation in 250 μL of pediatric clinical plasma samples. (A) The average number of sEVs isolated demonstrated no significant variation depending on technique. (B) DNA gel electrophoresis of EWS-ETS amplicon (~400 bp) illustrates the presence of the transcript in all of the patient samples *vs.* 50% of the samples isolated using the common EV tetraspanin CD9 alone.

| Cell Line | Age (years) | Diagnosis | t(11;22) | Fusion Type | Phase of Therapy | Clinical Status |
|-----------|-------------|------------------------------|----------|-------------|------------------|------------------------|
| TC-71 | 22 | Ewing Sarcoma | + | Type I | Post-therapy | Progressive Disease |
| RD-ES | 19 | Ewing Sarcoma | + | Type II | - | - |
| SK-ES-1 | 18 | Ewing Sarcoma | + | Type II | - | - |
| CHLA-258 | 14 | PNET | + | Type III | Post-therapy | Progressive Disease |
| COG-E-352 | 17 | PNET | - | EWS-ERG | Post-therapy | Recurrence |
| Hs919.T | 34 | Benign Osteoid Osteoma | - | None | - | - |

Data related to 5 ESFT cell lines comprised of both EWS-FLI1 and EWS-ERG oncogenic fusions and Hs919.T a benign bone tumor control cell line utilized in this study.

Supplementary Table 2: ESFT cell line derived sEV proteomic data. See Supplementary Table 2

Supplementary Table 3: Analysis of ESFT cell line derived sEV proteomic data. See Supplementary Table 3

Supplementary Table 4: Differential protein expression comparisons in ESFT sEVs. See Supplementary Table 4

Supplementary Table 5: Gene Set Enrichment Analysis (GSEA) comparison of EWS-FLI1 sEV and EWS-ERG sEV proteome. See Supplementary Table 5

| Symbol | Name | Symbol | Name |
|---------|---|---------|--|
| ACTG1 | actin gamma 1 | HSPA5 | heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
| ACTR3 | ARP3 actin-related protein 3 homolog (yeast) | HSPA8 | heat shock 70kDa protein 8 |
| ALDOA | aldolase A, fructose-bisphosphate | HSPD1 | heat shock 60kDa protein 1 (chaperonin) |
| ALDOC | aldolase C, fructose-bisphosphate | HUWE1 | HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase |
| ANXA1 | annexin A1 | ITGA5 | integrin, alpha 5 (fibronectin receptor, alpha polypeptide) |
| ANXA2 | annexin A2 | ITGB1 | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) |
| ANXA5 | annexin A5 | JAK1 | Janus kinase 1 |
| ARHGDIA | Rho GDP dissociation inhibitor (GDI) alpha | KRT1 | keratin 1, type II |
| BSG | basigin (Ok blood group) | KRT14 | keratin 14, type I |
| CALR | calreticulin | KRT9 | keratin 9, type I |
| CAV1 | caveolin 1, caveolae protein, 22kDa | MYH9 | myosin, heavy chain 9, non-muscle |
| CD99 | CD99 molecule | NGFR | nerve growth factor receptor |
| CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) |
| CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | PDIA3 | protein disulfide isomerase family A, member 3 |
| EIF2S1 | eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa | PFN1 | profilin 1 |
| ENO1 | enolase 1, (alpha) | PHB | prohibitin |
| ENO2 | enolase 2 (gamma, neuronal) | PKM | pyruvate kinase, muscle |
| EZR | ezrin | PLG | plasminogen |
| F2 | coagulation factor II (thrombin) | PRDX1 | peroxiredoxin 1 |
| FASN | fatty acid synthase | SLC16A1 | solute carrier family 16 (monocarboxylate transporter), member |
| FLNA | filamin A, alpha | SLC7A5 | solute carrier family 7 (amino acid transporter light chain, L system), member 5 |
| FLNC | filamin C, gamma | STMN1 | stathmin 1 |
| FSCN1 | fascin actin-bundling protein 1 | TFRC | transferrin receptor |
| FTH1 | ferritin, heavy polypeptide 1 | THBS1 | thrombospondin 1 |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | TLN1 | talin 1 |
| GSTP1 | glutathione S-transferase pi 1 | TPI1 | triosephosphate isomerase 1 |
| H2AFX | H2A histone family, member X | TPM3 | tropomyosin 3 |
| HINT1 | histidine triad nucleotide binding protein 1 | UCHL1 | ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) |
| HLA-A | major histocompatibility complex, class I, A | VCL | vinculin |
| HNRNPH1 | heterogeneous nuclear ribonucleoprotein H1 (H) | XRCC5 | X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) |
| HSPA4 | heat shock 70kDa protein 4 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma |

Supplementary Table 6: Proteins enriched in ESFT sEV sample

A total of 62 potential ESFT biomarker candidates were identified, which included both CD99/MIC2 and HINT1 in the ESFT sEV proteome.

| Protein Symbol | Gene | Location | Application | |
|-----------------|--|-----------------|---|--|
| HINT1 | Histidine triad nucleotide binding protein 1 | Intracellular | Prognosis | |
| CAV1 Caveolin 1 | | Plasma Membrane | Diagnosis | |
| NPM1 | Nucleolar phosphoprotein B23 | Intracellular | Disease Progression | |
| CTNNB1 | Cadherin-associated protein beta 1 | Intracellular | Diagnosis Disease Progression Prognosis | |
| ENO2 | Enolase 2 | Intracellular | Diagnosis Prognosis | |
| EZR | Ezrin | Plasma Membrane | Prognosis | |
| ITGA5 | Integrin, alpha 5 | Plasma Membrane | Prognosis | |
| JAK1 | Janus kinase 1 | Intracellular | Efficacy | |
| CD99 | CD99 molecule | Plasma Membrane | Diagnosis | |
| NGFR | Nerve growth factor receptor | Plasma Membrane | Disease Progression Prognosis | |

Supplementary Table 7: ESFT sEV proteins with biomarker applications

A total of 10 proteins previously identified to be associated with sarcomas were further investigated. 4 of the 10 proteins had been previously identified as diagnostic biomarker potential in sarcomas, while 6 of the 10 proteins were identified as prognostic biomarker potential in sarcomas.

Supplementary Table 8: Antibodies

| Antibodies | Isotype | Source | |
|--------------------------|---------|-------------------|--|
| CD99 (1C3) | Rabbit | Thermo Fisher | |
| NGFR (D4B3) | Rabbit | Cell Signaling | |
| HINT1 | Rabbit | ORIGENE | |
| ITGA5 | Rabbit | Cell Signaling | |
| JAK1 | Rabbit | Thermo Scientific | |
| CTNNB1 (14/Beta-Catenin) | Mouse | BD Biosciences | |
| EZR (3C12) | Mouse | Sigma Aldrich | |
| ENO | Rabbit | Cell Signaling | |
| NPM1 (NA24) | Mouse | Santa Cruz | |
| β-actin (AC-15) | Mouse | Sigma Aldrich | |

10 antibodies utilized for immunoblot analysis in ESFT sEV samples.